<DOC>
	<DOCNO>NCT02626611</DOCNO>
	<brief_summary>This phase 2 randomize , double-blind , placebo control study conduct multiple center U.S. All subject receive oral immunotherapy specific food allergy ( limited 5 food allergen Investigational New Drug ( IND ) 14831 ) . All subject receive Omalizumab 16 week . The subject 's allergen introduce rush desensitization day week 8 . Subjects return clinic escalate dose allergens 2,000mg protein allergen reach Subjects return clinic DBPCFC allergen week 30 . If subject nonreactive 2 allergen DBPCFC week 30 randomize one three double blind arm : Arm A- continue current dose ( 2000 mg food allergen protein ) , Arm B-300 mg food allergen protein , Arm C-placebo ( avoid food allergen protein ) , current dose . All subject return clinic DBPCFC allergen week 36 . The final challenge week 36 final end study visit . Safety paramount concern study design monitor carefully throughout study . Study subject parents/guardians receive extensive education food allergy reaction medication use .</brief_summary>
	<brief_title>Multi Immunotherapy Test Tolerance Xolair</brief_title>
	<detailed_description>The investigator enroll multi food allergic subject ( 4-55 year age ) proven multi food allergy . The investigator anticipate enrol 70 subject multi food allergy one site . Subjects must food specific Immunoglobulin E &gt; 4 kilo Units/Liter allergen skin test reactivity food allergen great equal 6mm wheal diameter . In addition , subject must total Immunoglobulin E &lt; 2,000 kilo Units/Liter , clinical reaction double blind placebo control food challenge ( DBPCFC ) food protein/powder establish sensitivity give food protein/powder ( pecan , milk , egg , peanut , almond , wheat , cashew , sesame seed , soy , walnut , hazelnut , shrimp , cod , salmon ) clinical reaction placebo ( oat ) per Chemistry Manufacturing Control section Investigational New Drug . Each subject plan enrol active phase study 36 week . Food protein powder obtain prepared per Investigational New Drug 14831 compliance applicable regulation . Omalizumab approve European Medicines Agency ( European FDA ) patient severe asthma &gt; 6 year age , US FDA patient &gt; 12 year age . Omalizumab dose accord Genentech Dosing Omalizumab provide site .</detailed_description>
	<mesh_term>Food Hypersensitivity</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Participant and/or parent guardian must able understand provide inform consent and/or assent applicable . Age 4 55 year moderate severe allergy milk and/or egg and/or peanut and/or almond and/or wheat and/or cashew and/or sesame seed and/or soy and/or pecan and/or walnut and/or hazelnut Positive skin prick test result great equal 6 mm wheal diameter allergen OR ImmunoCAP Immunoglobulin E ( IgE ) level &gt; 4 kilo Unit/Liter allergen A clinical reaction DBPCFC small dos food define &lt; dose 500 mg food protein No clinical reaction observe placebo ( oat ) challenge If female , must negative urine pregnancy test day ( use Clinical Laboratory Improvement Amendment ( CLIA ) approve urine test ) If female , childbearing potential , must agree compliant medicallyapproved method contraception ( please see Pregnancy section Patient Disposition protocol ) Plan remain study area research center trial Be train proper use Epinephrine autoinjector Avoid open blind food challenge allergen outside study Inability unwillingness participant/parent/guardian give write informed consent comply study protocol History cardiovascular disease History chronic disease ( asthma , atopic dermatitis , rhinitis ) require therapy ( e.g. , heart disease , diabetes ) , opinion Principal Investigator , would represent risk participant 's health safety study participant 's ability comply study protocol A total IgE screening &gt; 2,000 kU/L Previous adverse reaction Xolair A history severe anaphylaxis ( define require intubation admission ICU ) food allergen use study Unstable angina , significant arrhythmia , uncontrolled hypertension , current smoker , chronic sinusitis , chronic immunological disease , judgment investigator , might interfere evaluation administration test drug pose additional risk participant . Current use oral , intramuscular , intravenous corticosteroid , tricyclic antidepressant , betablockers ( oral topical ) Routine use medication could induce adverse gastrointestinal reaction study Refusing sign Epinephrine autoinjector Training Form Pregnant breast feed woman A history oat allergy ( since oat placebo agent DBPCFC ) , objective reaction screen DBPCFC oat Unwilling avoid food allergencontaining item except give part Oral Immunotherapy well food allergen allergic include 10 food list study Concurrent/prior use immunomodulatory therapy ( within 1 month ) ie , omalizumab , nontraditional form allergen immunotherapy ( e.g. , oral sublingual ) Severe asthma ( 2007 National Heart Lung Blood Institute ( NHLBI ) Criteria Steps 5 6 ) time enrollment Mild moderate asthma ( 2007 NHLBI Criteria Steps 14 ) time enrollment follow criterion meet : Forced Expiratory Volume one second ( FEV1 ) &lt; 80 % predict , FEV1/Forced Vital Capacity ( FVC ) &lt; 75 % , without controller medication ( age 6 great able spirometry ) Inhaled Corticosteroid ( ICS ) dose &gt; 220 mcg daily fluticasone ( equivalent inhale corticosteroid base NHLBI dose chart ) 1 hospitalization past year asthma ER visit asthma within past six month Use steroid medication ( Intravenous ( IV ) , Intramuscular ( IM ) oral ) follow manner history daily oral steroid dose &gt; 1 month past year steroid burst course ( 5 day ) 1 mg/kg prednisone ) course past 3 month &gt; 2 steroid burst course past year Use complementary alternative medicine ( CAM ) treatment modality ( e.g. , herbal remedy ) atopic and/or nonatopic disease within 90 day precede rush desensitization week 8or time . Inability discontinue antihistamine initial day escalation , skin test Oral Food Challenges ( OFCs ) Use investigational drug within 24 week participation Past current medical problem finding physical assessment laboratory test list , , opinion investigator , may pose additional risk participation study , may interfere participant 's ability comply study requirement may impact quality interpretation data obtain study .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>